Interleukin-5
US-FDASourced from openFDA
GET
/api/v1/drug/interleukin-5Indications
Sourced from openFDA- Take 15 minutes before meals.
Dosage & administration
Sourced from openFDADIRECTIONS Take 15 minutes before meals. Adults and children 12 years and older 20 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children between 12 years and 6 years of age 10 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children under 6 years 5 drops twice a day in a glass of water.
Warnings & precautions
Sourced from openFDAStop use and ask doctor if symptoms worsen or persist more than 5 days
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
357 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Off Label Use5315%
- 2Pyrexia349.5%
- 3Hypotension329.0%
- 4Fatigue236.4%
- 5Nausea236.4%
- 6Cardiotoxicity226.2%
- 7Chills226.2%
- 8Decreased Appetite195.3%
- 9Diarrhoea195.3%
- 10Malignant Neoplasm Progression195.3%
- 11Anaemia174.8%
- 12Disease Progression174.8%
- 13Product Use In Unapproved Indication154.2%
- 14Vomiting154.2%
- 15Death143.9%
Literature
Recent PubMed references pinned to Interleukin-5 as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review.Human vaccines & immunotherapeutics · 2026 · Park MJ, Han JK, Lam KK, et al.PMID 42234701DOI 10.1080/21645515.2026.2658911
- Bilateral temporal arteritis with multiorgan eosinophilic infiltration treated with IL-5 targeted antibody.Rheumatology international · 2026 · Murata K, Hishinuma T, Asashima H, et al.PMID 42207305DOI 10.1007/s00296-026-06149-6
- Beyond Eosinophil Depletion: IL-5 as a Context-Dependent Regulator of Airway Immune Networks.International journal of molecular sciences · 2026 · Cheng SLPMID 42123654DOI 10.3390/ijms27094077
- Pro-inflammatory and counter-regulatory modulators of interleukin-5-driven eosinophil programs: a framework for precision medicine in eosinophilic diseases.Frontiers in immunology · 2026 · Sasaki H, Miyata J, Fukunaga K, et al.PMID 42058205DOI 10.3389/fimmu.2026.1836661
- Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy.Frontiers in immunology · 2026 · Ou W, Wang Y, Hou C, et al.PMID 42039166DOI 10.3389/fimmu.2026.1817893
- Safety and efficacy of anti-IL-5 monoclonal antibodies as second-line therapy for chronic rhinosinusitis with nasal polyps: a meta-analysis.Frontiers in immunology · 2026 · Liao H, Qiu C, Luo Y, et al.PMID 41983135DOI 10.3389/fimmu.2026.1746573
- IL-5 promotes airway remodeling in asthma by mediating epithelial-mesenchymal transition via the AKT/NLRP3 pathway.International immunopharmacology · 2026 · Zhao L, Lin Y, Dou M, et al.PMID 41759267DOI 10.1016/j.intimp.2026.116422
- IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders.Journal of hematology & oncology · 2026 · Wu Y, Zhang R, Sun B, et al.PMID 41689037DOI 10.1186/s13045-026-01782-x
Clinical trials
The 10 most recently updated of 35 ClinicalTrials.gov registrations naming Interleukin-5 as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)Not yet recruiting · Phase 2 · Interventional · 96 enrolled · University Hospital, LilleNCT06734884updated 2026-05-15
- A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease ProgressionRecruiting · Observational · 50 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)NCT00091871updated 2026-05-07
- Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)Completed · Phase 4 · Interventional · 95 enrolled · Helsinki University Central HospitalNCT04823585updated 2026-03-24
- Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety TrialRecruiting · Phase 3 · Interventional · 123 enrolled · GlaxoSmithKlineNCT05334368updated 2025-11-25
- Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNPCompleted · Observational · 30 enrolled · Brigham and Women's HospitalNCT05672030updated 2025-11-24
- Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic BronchitisCompleted · Phase 3 · Interventional · 18 enrolled · McMaster UniversityNCT01463644updated 2025-09-24
- Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways DiseasesCompleted · Phase 4 · Interventional · 46 enrolled · McMaster UniversityNCT04765722updated 2025-09-16
- Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRIActive not recruiting · Interventional · 29 enrolled · Dr. Grace ParragaNCT03733535updated 2025-08-11
- Interleukin-2 (IL-2), Interleukin-5 (IL-5) and Interleukin-17 (IL-17) Levels of Patients With Stainless Steel CrownsCompleted · Observational · 12 enrolled · Yuzuncu Yil UniversityNCT06439095updated 2025-06-18
- Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life ConditionsCompleted · Observational · 246 enrolled · AstraZenecaNCT04184284updated 2024-12-09
Frequently asked questions
- What is Interleukin-5 used for?
- According to FDA labeling, Interleukin-5 carries indications including: Take 15 minutes before meals.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
Note. Data for
interleukin-5 is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.